Series A Biotech companies in Boston

We share a vision that potent, precise and safe medicines can be designed and developed for all diseases. Soufflé discovers and develops cell-specific ligands to deliver siRNA-based medicines that are rationally designed and transferred across the cell membrane to their target. We combine multiple proprietary technologies for identification of cell-specific receptors, ligand optimization and potent siRNA engineering to create and commercialize safer, stronger, and more durable medicines which will help improve patient lives.

• Series A
• 89 employees
• Founded 2021

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

• Series A
• 73 employees
• Founded 2017

Protein Metrics' vendor-neutral software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form. We innovate so that biopharmaceutical companies and university research labs can achieve confident results from their analysis and reporting. With our customers, we are boldly advancing protein characterization. For more information, visit http://www.proteinmetrics.com.

• Series A
• 56 employees
• Founded 2011

Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health.For more information, please visit www.spear.bio or email info@spear.bio.

• Series A
• 54 employees
• Founded 2021

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com.

• Series A
• 48 employees
• Founded 2020